Enso Ventures

Cognitive Geology Ltd, established in 2014 and based in Edinburgh, UK, specializes in developing advanced geological modeling software for the oil and gas industry. The company's innovative tools help geologists systematically analyze and mitigate the impacts of various geological processes, aiding in the discovery, appraisal, and development of both conventional and unconventional reserves, both onshore and offshore.

Neurovia, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, founded in 2013. The company focuses on developing therapies for neurological disorders, specifically targeting unmet medical needs in conditions such as X-linked adrenoleukodystrophy (X-ALD). Neurovia has created a selective thyromimetic agent aimed at treating X-ALD, a rare genetic disease that can lead to severe neurological deficits. By addressing these critical health challenges, Neurovia aims to improve the quality of life for patients affected by this condition.

UltraSoC Technologies Ltd., established in 2005 and headquartered in Cambridge, UK, specializes in semiconductor intellectual property (IP) for system monitoring, analysis, and optimization. The company's core offering is an independent, non-intrusive system-level architecture that enables real-time, wire-speed monitoring of System-on-Chip (SoC) internal behavior. This IP accelerates and de-risks development by providing engineers with insights into complex interactions between on-chip sub-systems, buses, and software. UltraSoC's toolkit comprises configurable modules and software for IP configuration, debug, and analytics, serving applications in SoC debug, analytics and optimization, in-field monitoring, and security. Since June 2020, UltraSoC operates as a subsidiary of Siemens AG.

Cavion LLC is a clinical-stage pharmaceutical company focused on developing therapies that restore the brain’s natural rhythms by modulating T-type calcium channels (Cav3), which are implicated in various neurological and rare genetic diseases. The company, founded in 2003 and based in Charlottesville, Virginia, with an additional office in Cambridge, Massachusetts, has developed CX-8998, a drug that targets these calcium channels in the nervous system. Cavion's innovative approach also extends to cancer treatment, as the company was the first to create therapies that engage Cav3 for solid tumors, with preclinical successes leading to Phase 1 clinical trials in brain cancer. The company's neurology program aims to deliver a novel class of non-addictive, non-opioid T-type calcium channel antagonists for conditions like neuropathic pain, essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. Cavion operates as a subsidiary of Jazz Pharmaceuticals plc, reflecting its commitment to advancing treatments that address critical medical needs in both oncology and neurology.

Galera Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics to mitigate radiotherapy-induced side effects in cancer patients. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule superoxide dismutase mimetic currently in Phase III trials for treating radiation-induced severe oral mucositis in head and neck cancer patients.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

SRJ Technologies Group specializes in developing and distributing weld-free coupling solutions for pipeline systems across various industries such as oil and gas, mining, utilities, and power generation. Established in 2011, the company offers products like SRJ couplings, repair clamps, and bespoke enclosure units, along with asset integrity management consulting services.

Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Cellectar Biosciences is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing cancer treatments. It specializes in phospholipid drug conjugates (PDCs), with CLR 131 being its lead candidate in Phase II trials for relapsed or refractory multiple myeloma and other B-cell malignancies.

Cambridge Nanotherm Limited is a company based in Haverhill, United Kingdom, specializing in the development and commercialization of advanced nano-ceramic technology for the electronics industry. Founded in 2010, the company focuses on thermal management solutions, particularly for LED applications and electronic substrates. Its primary product is the NANOTHERM metal-backed printed circuit board, which features a unique nano-ceramic dielectric layer applied directly to the surface of aluminum substrates. This innovative technology enhances thermal conductivity and dielectric strength, making it ideal for electronic interconnections. Additionally, Cambridge Nanotherm offers a chip-on-heat sink design specifically tailored for LED light engines, further solidifying its position in the thermal management market.

Carbodeon specializes in the development of nanomaterials, primarily focusing on nanodiamonds and graphitic carbon nitride. These materials enhance surface properties of composite materials, offering durability, low friction coatings, and improved thermal and mechanical performance for industrial manufacturing components.